Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

97.46 -2.29 (-2.30%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M.

Via The Motley Fool

Topics Earnings

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Q2 Earnings Call Highlights ↗

August 05, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining...

Via MarketBeat

Topics Earnings

Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat ↗

August 05, 2026

Via Chartmill

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗

May 06, 2026

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

August 05, 2026

Via Chartmill

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

July 29, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 13, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

June 14, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 11, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

June 04, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

May 30, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗

May 27, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and...

Via MarketBeat

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

May 21, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharma: A Rare Disease Growth Story to Watch ↗

May 20, 2026

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

Via MarketBeat

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗

May 07, 2026

This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Mirum (MIRM) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

May 04, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

May 03, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

April 29, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

April 27, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗

April 19, 2026

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗

April 13, 2026

This small biotech could grow much larger with some good news from its pipeline.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.